skip to main content
Show Results with:

Results 1 - 10 of 17  for Everything in this catalogue

results 1 2 next page
Refined by: author: Robert, Caroline remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Material Type:
Article
Add to My workspace

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

Daud, Adil I.; Wolchok, Jedd D.; Robert, Caroline

Journal of clinical oncology -- American Society of Clinical Oncology -- Volume: 34 34; (pages 4102-4109) -- 2016

Check library holdings

2
Material Type:
Article
Add to My workspace

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III

Grob, Jean Jacques et al.

European journal of cancer. Volume 91 (2018); pp 168-170 -- Elsevier

Online access

3
Material Type:
Article
Add to My workspace

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

Hamid, Omid et al.

British journal of cancer. Volume 119:Issue 6 (2018); pp 670-674 -- Springer Nature

Online access

4
Material Type:
Article
Add to My workspace

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III

Grob, Jean Jacques et al.

European journal of cancer. Volume 91: (2018, March); pp 168-170 -- Elsevier

Online access

5
Material Type:
Article
Add to My workspace

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

Schadendorf, Dirk et al.

Elsevier -- 2016

Online access

6
Material Type:
Article
Add to My workspace

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Schachter, Jacob et al.

The lancet. Volume 390:Issue 10105 (2017); pp 1853-1862 -- Elsevier

Online access

7
Material Type:
Article
Add to My workspace

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Carlino, Matteo S. et al.

European journal of cancer. Volume 101 (2018); pp 236-243 -- Elsevier

Online access

8
Material Type:
Article
Add to My workspace

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Schachter, Jacob et al.

The lancet. Volume 390:Issue 10105 (2017); pp 1853-1862 -- Elsevier

Online access

9
Material Type:
Article
Add to My workspace

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

Hamid, Omid et al.

European journal of cancer. Volume 86: (2017, November); pp 37-45 -- Elsevier

Online access

10
Material Type:
Article
Add to My workspace

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Carlino, Matteo S. et al.

European journal of cancer. Volume 101: (2018, September); pp 236-243 -- Elsevier

Online access

Results 1 - 10 of 17  for Everything in this catalogue

results 1 2 next page

Refine Search Results

Refine my results

Access Options 

  1. Request to Reading Room  (13)
  2. Online: Reading Room only  (10)
  3. Purchase a copy  (8)
  4. Refine further open sub menu

Creation date 

From To

Additional Features 

  1. Abstract  (14)
  2. No Abstract  (3)
  3. Refine further open sub menu

Try a new search

Ignore my search and look for everything

by this Author/Contributor:

  1. Robert, Caroline
  2. Daud, Adil
  3. Ribas, Antoni
  4. Hamid, Omid
  5. Schachter, Jacob

Searching Remote Databases, Please Wait